Literature DB >> 24401217

Airflow limitation in smokers is associated with arterial stiffness: the Nagahama Study.

Yasuharu Tabara1, Shigeo Muro2, Yoshimitsu Takahashi3, Kazuya Setoh4, Takahisa Kawaguchi4, Chikashi Terao4, Shinji Kosugi5, Akihiro Sekine6, Ryo Yamada4, Takeo Nakayama3, Michiaki Mishima2, Fumihiko Matsuda4.   

Abstract

BACKGROUND: Pathophysiological mechanisms of associations between airflow limitation (AL) and arterial stiffness remain unclear. One factor that might affect both AL and arterial stiffness is habitual smoking. The aim of this study is to investigate a possible interaction of smoking on the association between AL and arterial stiffness.
METHODS: Study subjects consisted of 8790 apparently healthy community residents. Airflow limitation was defined as a ratio of forced expiratory volume in 1 s (FEV1) to forced vital capacity of less than 70%. Brachial-to-ankle pulse wave velocity (baPWV) was used as an index of arterial stiffness. Smoking habit was investigated using a structured questionnaire.
RESULTS: Subjects with AL had significantly higher baPWV (AL 1381 ± 334, control 1261 ± 227 cm/s, p < 0.001). In a separate analysis by smoking habit, advanced arterial stiffness in AL was observed only in smokers (non-smokers: AL 1300 ± 220, control 1260 ± 218; smokers: AL 1436 ± 384, control 1264 ± 243 cm/s). Other clinical features of subjects with AL were older age; increased plasma hsCRP levels; and a high prevalence of male sex, hypertension, and smoking experience. Multiple linear regression analysis adjusted for these covariates identified the smoking × AL interaction as an independent determinant of baPWV (β = 0.066, p < 0.001). Conversely, baPWV was an independent determinant of AL in current and past smokers, but not in never smokers.
CONCLUSIONS: AL arising from cigarette smoking, but not AL in non-smokers, was associated with arterial stiffness in a general population independently of established risk factors. Measurement of subclinical arterial change in smokers may be useful in identifying persons at risk for AL.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Airflow limitation; Arterial stiffness; Chronic obstructive pulmonary diseases; Pulse wave velocity; Smoking

Mesh:

Substances:

Year:  2013        PMID: 24401217     DOI: 10.1016/j.atherosclerosis.2013.10.020

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.

Authors:  Surya P Bhatt; Mark T Dransfield; John R Cockcroft; Jie Wang-Jairaj; Dawn A Midwinter; David B Rubin; Catherine A Scott-Wilson; Courtney Crim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-01-19

2.  Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine).

Authors:  Mariana Muñoz-Esquerre; Elisabet Aliagas; Marta López-Sánchez; Ignacio Escobar; Daniel Huertas; Rosa Penín; Jordi Dorca; Salud Santos
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

3.  Study the association of chronic obstructive pulmonary disease with early endothelial dysfunction and its impact on cardiovascular system by estimating urinary albumin creatinine ratio.

Authors:  Anand Agrawal; Renu Garg; Dibakar Sahu; Mukesh Kumar
Journal:  Lung India       Date:  2017 Mar-Apr

4.  Relationship between pulmonary function and peripheral vascular function in older Chinese: Guangzhou biobank cohort study-CVD.

Authors:  Jing Pan; Lin Xu; Tai Hing Lam; Chao Qiang Jiang; Wei Sen Zhang; Feng Zhu; Ya Li Jin; G Neil Thomas; Kar Keung Cheng; Peymane Adab
Journal:  BMC Pulm Med       Date:  2018-05-21       Impact factor: 3.317

5.  Arterial stiffness in adults with steady-state bronchiectasis: association with clinical indices and disease severity.

Authors:  Yong-Hua Gao; Juan-Juan Cui; Ling-Yun Wang; Ke-Qin Yin; Li Wang; Guo-Jun Zhang; Shao-Xia Liu
Journal:  Respir Res       Date:  2018-05-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.